FDA
-
-
-
-
-
-
-
AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
-
-
-
-
-
-
-
AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression
-
-
-
-
-
-
-
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
-
-
-
-
-
-
-
atai Life Sciences (ATAI) and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Commences Phase 2b proof-of-concept trial of RL-007
-
-
-
-
-
-
-
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
-
-
-
-
-
-
-
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

